RECLIPSEN SUMMARY
RECLIPSEN™
(Desogestrel and Ethinyl Estradiol Tablets)
Rx only
RECLIPSEN™ Tablets provide an oral contraceptive regimen of 21 white round tablets each containing 0.15 mg desogestrel (13-ethyl-11-methylene-18, 19-dinor-17 alpha-pregn-4-en-20-yn-17-ol) and 0.03 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3, 17, diol).
RECLIPSEN™ Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
|
NEWS HIGHLIGHTSMedia Articles Related to Reclipsen (Desogestrel / Estradiol)
US funding revamps African contraceptive drive (AFP)
Source: Y! Health News Search RSS Feed [2009.11.18]
AFP - A new 12 million dollar family planning drive launched here Wednesday highlights how Obama administration funding has revamped a contraception drive in Africa and developing states, UN officials said, noting a sharp turnaround from the Bush era.
Terrence Higgins Trust Welcomes Department Of Health Nursing Degree Announcement, UK
Source: HIV / AIDS News From Medical News Today [2009.11.15]
HIV and sexual health charity Terrence Higgins Trust has welcomed the announcement by the Department of Health that all new nurses will be educated to degree level from 2013. Terrence Higgins Trust (THT) currently employs nurses who work in Chlamydia screening programmes for young people, HIV testing clinics and clinics that offer contraception services and screening for sexually transmitted infections.
Published Studies Related to Reclipsen (Desogestrel / Estradiol)
Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. [2009.07]
BACKGROUND: The study was conducted to investigate whether hormonal contraceptives administered via the oral and vaginal route exert a similar effect on insulin sensitivity (SI)... CONCLUSIONS: The present data indicate that in contrast to OC use, vaginal contraception with the ring does not deteriorate SI. The vaginal ring may represent an appropriate choice for long-term contraception in women at risk for developing diabetes mellitus or metabolic syndrome.
Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. [2009.02]
BACKGROUND: Second-generation and third-generation oral contraceptives containing 30 mcg or more of ethinylestradiol (EE) decrease insulin sensitivity (SI). In this study, we investigated whether SI is decreased by contraceptives containing lower doses EE or by progestins with antiandrogenic properties... CONCLUSIONS: The present study confirms that DSG, even when associated with low EE dose, decreases SI. By contrast, EE/CMA does not deteriorate SI and induces a favorable lipid profile.
Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. [2007.12]
OBJECTIVE: To assess the effect of a new progestin progestogen only pill (desogestrel) versus an oral contraceptive in the treatment of recurrent endometriosis... CONCLUSIONS: Both desogestrel and an oral estro-progestinic were effective, safe and low cost therapy of pain symptoms after endoscopic surgery for endometriosis, the former showing an impact on breakthrough bleeding, the later an incidence on body weight increase.
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. [2006.04]
PURPOSE: In this open-label, randomized study, we assessed the effects on hemostasis of two combined oral contraceptives containing drospirenone (DRSP) as progestogen component... CONCLUSION: The changes in the hemostatic variables for DRSP/20EE were less pronounced compared to DSG/30EE and DRSP/30EE. The results were in accordance with previous reports on effects of similar OCs.
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. [2005.06]
OBJECTIVE: To compare the effect of ethinyl estradiol 20 microg/drospirenone 3 mg (EE 20 microg/DRSP 3 mg) administered according to a 24/4 regimen with ethinyl estradiol 20 microg/desogestrel 150 microg (EE 20 microg/DSG 150 microg) administered according to the conventional 21/7 regimen on lipid, carbohydrate and hemostatic parameters... CONCLUSION: EE 20 microg/DRSP 3 mg has a good safety profile comparable with EE 20 microg/DSG 150 microg.
Clinical Trials Related to Reclipsen (Desogestrel / Estradiol)
Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents [Recruiting]
The primary purpose of this study is to compare the compliance rates of adolescents who take
oral contraceptives (OCPs) continuously to those who take OCPs cyclically.
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception [Completed]
The purpose of this study is to compare the efficacy and safety of Yasmin® and Marvelon® in
Chinese women requiring contraception
Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients [Recruiting]
Hundreds of thousands of couples in the United States experience infertility each year.
When initial measures do not help, some couples require a process called ovarian stimulation
and in vitro fertilization (IVF). Usually, a woman produces at most one egg each month.
Ovarian stimulation helps these women make more than one egg per month. However, this
involves taking hormones that stimulate the ovary to produce many eggs at one time. The
stimulatory hormones injected with a small needle. The eggs are removed from the ovary
through a surgical procedure and then placed in a dish for fertilization by sperm to form
embryos. The embryos are grown in the laboratory then replaced into the woman's uterus 3-5
days later.
The stimulation of the ovaries is important. Some patients undergo ovarian stimulation for
IVF but do not respond to the treatment. This is a very difficult situation because even
though several ovarian stimulation protocols have been used for poor responder patients, it
is not clear which protocol works best. In fact, two of the most commonly used protocols
have not been directly compared.
This study will randomize (like flipping a coin) couples with a history of low response who
are going to start IVF treatment into two groups. In one group the female partner will use
a protocol called "E2 patch/antagonist". These women will use an estrogen patch and
injected antagonist for several days before starting injectable fertility medications. The
other group will use a protocol called "OCP/microdose". This group of women will use oral
contraceptive pills (OCPs) and small doses of lupron along with the other injectable
fertility medications. We will then follow their progress to see how many eggs they produce
and how many women get pregnant.
Hormonal Contraception & Vaginal Health [Recruiting]
The purpose of this study is to help determine if the route by which women receive hormonal
contraception causes different changes to occur in the lining of the vagina. We plan to
compare an oral route (taking birth control pills) with a vaginal route (using a vaginal
ring).
Mid-Luteal Phase Synchronization of Ovarian Folliculogenesis in Women [Recruiting]
We hypothesize that administration of an aromatase inhibitor (AI) and hormonal
contraceptives (HC) in the mid-luteal phase of the menstrual cycle will result in atresia of
the follicles in the extant wave and cause synchronous re-emergence of a new follicular
wave. We anticipate that this will provide us with information to facilitate the development
of a new method for ovarian synchronization; a safer, more effective ovulation induction
therapy; a new method for emergency contraception; and a greater understanding of human
folliculogenesis.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Reclipsen has an overall score of 10. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Reclipsen review by 31 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | skin breakouts/birth control |
| Dosage & duration: | | 0.15 mg, .03 mg taken one pill per day for the period of one year |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Treatment benefits include clear, glowing skin, regular menstrual cycles, and reliable birth control. |
| Side effects: | | Treatment side effects include breast tenderness for about a month after first doseage, and some ovular soreness. |
| Comments: | | Treatment details include taking a pill eachday at the same time for maximum effectiveness in preventing pregnancy, and taking the 5 placebo pills to help remember to take a pill every day. |
|
|
